The final coverage decision is designed to provide access to Medicare beneficiaries in the early stages of Alzheimer's while ensuring the safety and effectiveness of Biogen’s Aduhelm. Beneficiaries will have access to the drug once they enroll in an approved FDA or NIH trial designed to better determine whether the drug slows the...
